<DOC>
	<DOCNO>NCT01353794</DOCNO>
	<brief_summary>The objective Non-Interventional study evaluate effectiveness &amp; safety Nexavar advance Renal Cell Carcinoma ( RCC ) patient daily-life treatment condition base age patient ( old ( age &gt; 70 year ) young patient ( age &lt; 70 year ) . Specifically investigated tumor status , duration Nexavar Â® treatment ( number cycle ) incidence Hand foot Skin Reaction .</brief_summary>
	<brief_title>Study Observe Safety Efficacy Nexavar Treatment Kidney Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patients diagnosis advance Renal Cell Carcinoma ( RCC ) decision take investigator prescribe Sorafenib Exclusion criterion must read conjunction local product information .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>SORAFENIB</keyword>
	<keyword>RENAL CELL CARCINOMA</keyword>
	<keyword>TYROSINE KINASE INHIBITOR</keyword>
	<keyword>OBSERVATIONAL STUDY</keyword>
</DOC>